This funding will enable PsyPAN to continue and strengthen its focus on improving participant wellbeing and the safe delivery of PAT. Core funding covers running costs and the continuation of PsyPAN's core activities, keeping the organisation operational and independent as large-scale PAT clinical trials increase across Europe and the need for participant support grows.
PsyPAN was founded in 2021 by two former clinical trial participants, Ian Roullier and Leonie Schneider, who each received psilocybin-assisted therapy at Imperial College and King's College London. Since then, PsyPAN has built a global community, 70% based in Europe, of people who have received PAT in legal clinical trials, and in late 2024 launched its first peer support groups. The organisation is led by Co-Director Ian Roullier, who brings experience in charity communications from Missing People and Mind.
With this support, PsyPAN aims to connect and support more people with lived experience of PAT, encouraging the sector to adopt ethical, participant-centric best practices and building public understanding of PAT. By producing research and white papers, co-creating media guidelines for journalists, and building patient and public involvement partnerships, PsyPAN intends to strengthen safeguarding, amplify participant voices and continue the destigmatisation of PAT, laying the groundwork for its continued growth.
